Compare LOCL & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LOCL | ALXO |
|---|---|---|
| Founded | 2021 | 2015 |
| Country | United States | United States |
| Employees | 333 | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.6M | 68.3M |
| IPO Year | N/A | 2020 |
| Metric | LOCL | ALXO |
|---|---|---|
| Price | $1.15 | $2.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 22.7K | ★ 746.9K |
| Earning Date | 01-01-0001 | 06-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 26.36 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $36.93 | N/A |
| Revenue Next Year | $82.62 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.98 | $0.41 |
| 52 Week High | $5.75 | $2.66 |
| Indicator | LOCL | ALXO |
|---|---|---|
| Relative Strength Index (RSI) | 28.07 | 51.69 |
| Support Level | N/A | $2.01 |
| Resistance Level | $2.75 | $2.27 |
| Average True Range (ATR) | 0.14 | 0.20 |
| MACD | -0.02 | -0.05 |
| Stochastic Oscillator | 16.06 | 21.88 |
Local Bounti Corp is a controlled environment agriculture company. Its business model is based on building local facilities, operated by local teams, to deliver fresh and quality produce to local communities while maintaining a limited carbon footprint. Using proprietary technology to grow leafy greens and herbs in smart greenhouses with a cultivation process that uses less water and land than conventional agriculture, free from herbicides or pesticides, it delivers products that have a longer shelf life, and are good in taste.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.